ARQ 197 demonstrates 66 percent improvement in median PFS in patients with advanced NSCLC ArQule.

Improvement in median PFS was more pronounced in the pre-defined sub-group of individuals with non-squamous histology ; median PFS was 18.9 weeks in the treatment arm versus 9.7 weeks in the control arm, which represents a 94 percent improvement. Predicated on an exploratory Cox regression analysis, the endpoint of PFS was fulfilled in the sub-group and attained statistical significance . There have been no clinically relevant differences in adverse event rates between your control and treatment arms. Nearly all adverse events were gentle in intensity and included rash, fatigue and diarrhea.Greisman, M.D., Ph.D., Chris Fisher, Ph.D., David J. Weatherall, F.R.C.P., F.R.S., Daniel Electronic. Sabath, M.D., Ph.D., Indicate Groudine, M.D., Ph.D., Stuart H. Orkin, M.D., Anuja Premawardhena, F.R.C.P., D.Phil., and M.A. Bender, M.D., Ph.D.1-3 Furthermore, the process is a paradigm for developmental gene regulation and expression. Recent insight into hemoglobin switching offers come from the results of genomewide association studies of the genetic basis for normal variation in fetal hemoglobin levels. Comprehensive work over an interval of three decades has implicated these sequences in the regulation of the locus. Huge deletions from within the locus through regions far upstream have already been found to result in underexpressed or silent thalassemic alleles, leading to the identification of an upstream enhancer, the locus control area.